ABVC BioPharma, Inc. (NASDAQ: ABVC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reporting total assets of $21.06 million, a 179% increase from $7.54 million in 2024. The significant balance sheet expansion was primarily fueled by strategic acquisitions of land and development-oriented assets in Asia, with net property and equipment rising to $12.84 million from $511,088. The company’s management views 2025 as a transformative year that structurally strengthened its asset foundation.
The company has adopted an asset-backed licensing model, licensing its core drug programs to subsidiary and related parties: CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, the subsidiaries handle clinical development, reducing ABVC’s direct cash burn while the company retains licensing economics and equity participation. This approach separates development risk from long-term value participation, according to management.
In parallel, ABVC has expanded its physical asset base in Taiwan. The company holds a 5,995.41 square meter property in Longtan District, Taoyuan, valued at $4.6 million as of December 31, 2025. This land is held as a strategic reserve asset with potential for healthcare-related applications or biotechnology infrastructure. Additionally, a 69,230.90 square meter site in Puli Township, Nantou, independently appraised at approximately $8.0 million as of January 30, 2026, is being developed as a staged, long-term initiative. The Puli plan includes establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, and creating an agricultural-biotech integration platform. Projected annual cultivation and processing output value is estimated between $60,000 and $360,000, depending on processing depth.
Management noted that the title transitions for these land assets are under government review in Taiwan, with final holding structures to be determined in accordance with local regulations. The company’s evolution toward a hybrid asset model combines intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets.
ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device, ABV-1701/Vitargus®, under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal Phase III clinical trials through global partnerships.
